PharmiWeb

HLA Typing Market is Expected to Reach CAGR of 6% by the End of 2030

The global HLA typing market is expected to expand at a compound annual growth rate (CAGR) of approximately 6% during the ...
News Medical

HLA-DRB1 molecule can be a potential target in treating acute myeloid leukemia

One main goal of anti-cancer therapies is to kill tumor cells without affecting the surrounding normal cells. Therefore, many drugs are designed to target tumor-specific antigens, which are molecules ...
Yahoo Finance

Human Leukocyte Antigen (HLA) Targeted Therapy Market Research 2026: Advances Driven by Novel CAR-Treg and Bispecific T-Cell Engager Programs from Quell Therapeutics and ...

Dublin, Dec. 02, 2025 (GLOBE NEWSWIRE) -- The "Human Leukocyte Antigen (HLA) Targeted Therapy, Clinical Trials, Therapeutic Approaches & Market Opportunity Insight 2026" report has been added to ...
Morningstar

RheumaGen Presents HLA Gene-Editing Preclinical Data for Nearly Universal Autoimmune Disease Target at ACR Convergence 2025 Oral Session

AURORA, Colo., Oct. 28, 2025 /PRNewswire/ -- RheumaGen, Inc., a cell and gene therapy company engineering a new class of therapeutics to cure common autoimmune diseases, today announced groundbreaking ...
ascopubs.org

Molecular signatures of class II HLA and p-16 status as an immune-based classification of OPSCC relying on known predictors of sensitivity to PD-1 blockade.

Association of mannitol (MAN) with cisplatin (CIS)-induced nephrotoxicity (NTX) and cumulative CIS dose (CCD). This is an ASCO Meeting Abstract from the 2017 ASCO Annual Meeting I. This abstract does ...
Mena FN

Human Leukocyte Antigen (HLA) Targeted Therapy Market Research 2026: Advances Driven By Novel CAR-Treg And Bispecific T-Cell Engager Programs From Quell Therapeutics And ...

(MENAFN- GlobeNewsWire - Nasdaq) The market for Human Leukocyte Antigen (HLA) targeted therapies is expanding, with the first therapy approval expected by 2030. Key opportunities include developing ...